Business News • PR NewsWire • Johnson & Johnson Pharmaceutical Research & Development Reports Phase 2b Clinical Trial Results Evaluating Canagliflozin to Treat Type 2 Diabetes

Johnson & Johnson Pharmaceutical Research & Development Reports Phase 2b Clinical Trial Results Evaluating Canagliflozin to Treat Type 2 Diabetes

Johnson & Johnson Pharmaceutical Research & Development Reports Phase 2b Clinical Trial Results Evaluating Canagliflozin to Treat Type 2 Diabetes

ORLANDO, Fla., June 26 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 (SGLT2) inhibitor, improved glycemic control, and was also associated with

View More : http://www.prnewswire.com/news-releases/johnson--johnson-pharmaceutical-research--development-reports-phase-2b-clinical-...

Releted News by prnewswire

Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes

Film Independent Announces Jury Award Winners of 2010 Los Angeles Film Festival, Presented by The Los Angeles Times

Cedar Point's New Shoot the Rapids Water Ride Opens for the Summer!

Concierge Auctions Successfully Sells Felicity Farm, an Exquisite 15.8-Acre Estate in Wawa, Pennsylvania, During a Live, On-site Auction

Young & Rubicam is Young Again: Global Content Giant's Renaissance